Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo

BACKGROUND: In this analysis we report patients with advanced gastrointestinal stromal tumors (GIST) refractory to imatinib and sunitinib therapy as derived from the EuroQol-5D (EQ-5D) for progression-free (PF) and progressive disease health status. METHODS: Data were analyzed from a phase III trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Poole, Chris D., Connolly, Mark P., Chang, Jane, Currie, Craig J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511071/
https://www.ncbi.nlm.nih.gov/pubmed/24957256
http://dx.doi.org/10.1007/s10120-014-0391-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511071/
https://www.ncbi.nlm.nih.gov/pubmed/24957256
http://dx.doi.org/10.1007/s10120-014-0391-x

Ejemplares similares